Login to Your Account

Clinic Roundup

Wednesday, November 23, 2011
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported a 23.2-month median overall survival (OS) from a single-arm Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with locally advanced or metastatic breast cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription